The Population Council, Inc.

The Population Council, Center for Biomedical Research

The Population Coucil, Center for Biomedical Research

Alfred J Moo-Young

Horacio Bruno Croxatto

Saleh Ismail Saleh

Saleh I Saleh

Ana Zepeda-Ortega

The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

Androgen as a male contraceptive and non-contraceptive androgen replacement

This invention features an implantable system for use as a male contraception and as a treatment of benign prostate hypertrophy and other conditions. The implant system includes an implant intended for subcutaneous or local administration having a core comprising a silicone elastomer and drug matrix which is encased in an ethyl vinyl acetate coating or membrane.

Silicone core long term androgen delivery implant

Disclosed is a subdermally implantable drug-delivery device, which contains: a central core extending in an axial direction and having an outer surface and opposing ends, which core includes a matrix of a pharmaceutically effective amount of a subdermally administrable drug substantially uniformly dispersed in a polymeric base material; an intermediate polymeric layer overlying the outer surface of the central core; and an outer polymeric layer overlying the intermediate layer, wherein the intermediate layer controls the rate of diffusion of the drug from the central core to the outer layer. In preferred embodiments, the subdermally administrable drug is a contraceptive agent such as the 16-methylene-17-.alpha.-acetoxy-19-norprogesterone-progestin; the polymeric base material and the outer polymeric layer each contain a polydimethylsiloxane such as Silastic.RTM.; and the intermediate layer contains a porous material such as cellulose. The devices provide for the substantially zero-order release of the drug for their intended lifetime without initial overdosing of the drug.

Contraceptive method using a subdermally implantable device

The present invention relates to implantable male contraceptive devices. An ethylene vinyl acetate copolymer based implant is described for delivery of an androgen and a system including an ethylene vinyl acetate copolymer based implant as well as a second implant are described for the administration of both androgen and a sterilitant. These implants may be used to provide contraception for men, as well as, for hormone therapy, treatment of enlarged prostate and other aliments.

Male contraceptive implant

Disclosed is a subdermally implantable drug-delivery device, which contains: a central core extending in an axial direction and having an outer surface and opposing ends, which core includes a matrix of a pharmaceutically effective amount of a subdermally administrable drug substantially uniformly dispersed in a polymeric base material; an intermediate polymeric layer overlying the outer surface of the central core; and an outer polymeric layer overlying the intermediate layer, wherein the intermediate layer controls the rate of diffusion of the drug from the central core to the outer layer. In preferred embodiments, the subdermally administrable drug is a contraceptive agent such as the 16-methylene-17-.alpha.-acetoxy-19-norprogesterone progestin; the polymeric base material and the outer polymeric layer each contain a polydimethylsiloxane such as Silastic.RTM.; and the intermediate layer contains a porous material such as cellulose. The devices provide for the substantially zero-order release of the drug for their intended lifetime without initial overdosing of the drug.

Growing community of inventors

Hastings-on-Hudson, NY, United States of America

Alfred J Moo-Young